Open Microphone Meeting:
|
|
- Scot Harrell
- 8 years ago
- Views:
Transcription
1 Open Microphone Meeting: USP General Chapter <797> Pharmaceutical Compounding Sterile Preparations October 21, :00 p.m. to 4:00 p.m. EDT
2 Agenda Welcome Overview of USP s Revision Process Overview of Revised General Chapter <797> Pharmaceutical Compounding Sterile Preparations Background Overview of Revised Content Information on How to Submit Comments Timeline and Next Steps Question & Answer Session 2
3 3 Overview of the U.S. Pharmacopeial Convention
4 About USP Scientific non-profit organization that sets standards for the identify, strength, quality, and purity of medicines, food ingredients, and dietary supplements USP s drug standards are enforceable in the United States by the Food and Drug Administration, and these standards are used in more than 140 countries USP Headquarters Rockville, MD 4
5 5
6 Compounding Expert Committee Chair: Gigi Davidson, B.S. Pharm, DICVP, NC State College of Veterinary Medicine Lisa Ashworth, B.S. Pharm Gus Bassani, Pharm.D. Ruth Ebiasah, Pharm.D., M.S. Edmund Elder, Ph.D., B.S. Pharm Ryan Forrey, Pharm.D., M.S. Deborah Houston, Pharm.D. Brenda Jensen, M.A. Patricia Kienle, MPA, B.S. Pharm 6
7 Compounding Expert Committee Chair: Gigi Davidson, B.S. Pharm, DICVP, NC State College of Veterinary Medicine William Mixon, B.S. Pharm John Musil, Pharm.D. David Newton, Ph.D. Alan Parr, Pharm.D., Ph.D. Abby Roth, B.Sc. Robert Shrewsbury, Ph.D. Connie Rae Sullivan, B.S. Pharm James Wagner Brenda Yuzdepski, B.S. Pharm 7
8 Overview of Development Process Revision proposed by stakeholder, USP EC, or USP Staff Proposal published in PF for 90-day public comment Based on the nature and significance of the public comments Forward Defer Cancel Ballot Approve Not approve Proposal republished for public comment 8
9 9 General Chapter <797> Pharmaceutical Compounding Sterile Preparations Gigi Davidson, BSPh, DICVP Chair, USP Compounding Expert Committee,
10 USP <797>: Revision Proposal Chapter History First Published in 2004 (USP27-NF22) First Revised in 2008 (USP 31-NF26 2S) Purpose of Revision To reflect new science and evidence based on updated guidance documents, best practices, and new learnings from investigations Respond to stakeholder input received throughout the cycle Clarify topics that are frequently queried and misconstrued 10
11 USP <797>: Background July 2010 Early 2013 April 2013 <797> subcommittee formed & began work Collaboration with Microbiology Expert Committee Formed <797> Expert Panel June 2015 <797> subcommittee completed work Sept Pre-post <797> for Public Comment 11
12 USP <797>: Overview of Major Changes Reorganized chapter Procedural information placed in Boxes Categories of CSPs Collapsed into two categories Category 1 CSPs BUD 12 hours at room temperature or 24 hours refrigerated PEC placed in a segregated compounding area Category 2 CSPs BUD > 12 hours at room temperature or > 24 hours refrigerated PEC placed in a classified area 12
13 USP <797>: Overview of Major Changes Hazardous Drugs Removed all handling information and replaced with crossreference to <800> Hazardous Drugs Handling in Healthcare Settings Scope Administration should follow CDC s Safe Injection Practices Reconstitution and dilution strictly in accordance to manufacturer s labeling not within scope of chapter Repackaging must be performed following the requirements in the chapter Urgent-Use CSPs (previously termed Immediate-Use CSPs ) Reserved for rare circumstances where a CSP is urgently needed 13
14 USP <797>: Overview of Major Changes Personnel Qualifications Reevaluation and Requalification Visual observation Gloved Fingertip Sampling Media-fill testing Proposed Frequency Initially and then quarterly 3 times initially and then quarterly Initially and then quarterly Personnel Protective Equipment Based on CSP Category and type of PEC Requirement for sterile sleeves (or sterile gown) 14
15 USP <797>: Overview of Major Changes Buildings and Facilities Primary Engineering Controls (PEC) new terminology Laminar Airflow System (LAFS) Restricted Access Barrier System (RABS) Isolator Placement of PEC Category 1 CSPs PEC may be placed in an unclassified Segregated Compounding Area Category 2 CSPs LAFS, BSC, and RABs must placed in an ISO Class 7 or better area Isolator must be placed in ISO Class 8 area 15
16 USP <797>: Overview of Major Changes Environmental controls Well-lit and comfortable conditions Temperature 20 or cooler Humidity below 60% Environmental Monitoring Proposed Frequency Nonviable Air Sampling Viable Air Monitoring Surface Sampling Every 6 months Monthly Monthly 16
17 USP <797>: Overview of Major Changes Documentation Master formulation records Compounding records Release Testing Sterility testing (refers to <71> Sterility Test) For batch sizes < 40, number of units to be tested is 10% rounded up to the next whole number Endotoxin Testing Required for Category 2 CSPs prepared from nonsterile ingredients (except inhalation and topical ophthalmic) Exception if endotoxin burden is predetermined (i.e. certificate of analysis) 17
18 USP <797>: Overview of Major Changes Establishing Beyond-Use Dates Based On Method of Achieving Sterility Starting Components Sterility Testing Preservative Storage Conditions New terminology for In-Use Times Time before which a conventionally manufactured product or CSP must be used after it is opened or punctured 18
19 USP <797>: Revision Proposal Roadmap Through Chapter 1. Introduction and Scope 2. Personnel Qualifications Training, Evaluation, and Requalification 3. Personal Hygiene and Personal Protective Equipment 4. Buildings and Facilities 5. Environmental Monitoring 6. Cleaning and Disinfecting Compounding Areas 7. Equipment and Components 8. Sterilization and Depyrogenation 9. SOPs and Master Formulation and Compounding Records 10. Release Testing 11. Labeling 19
20 USP <797>: Revision Proposal Roadmap Through Chapter 12. Establishing Beyond-Use Dates and In-Use Times 13. Quality Assurance and Quality Control 14. CSP Storage, Handling, Packaging, and Transport 15. Complaint Handling and Adverse Event Reporting 16. Documentation 17. Radiopharmaceuticals as CSPs Glossary Appendix 1. Acronyms Appendix 2. Common Disinfectants Used in Health Care for Inanimate Surfaces and Noncritical Devices, and Their Microbial Activity and Properties 20
21 USP <797>: How to Submit Comments General Chapter <797> is posted online at proposed-revision Download and complete the submission template submission template to Comments due January 31 st,
22 USP <797>: How to Submit Comments Provide all information in the event we need to contact you any follow-up Provide comments that do not have any corresponding line numbers. Provide comments with corresponding line numbers. Include specific suggestions and rationale. 22
23 USP <797>: Timeline and Next Steps Date Sept 25, 2015 Sept 25, 2015 through Jan 31, 2016 Oct 21, 2015 Jan 31, 2016 Activity Revised General Chapter <797> Posted for Public Comment Open Public Comment Period Open Microphone Web Meeting Deadline for Submitting Public Comments Next steps Subcommittee will review ALL comments submitted Comments will be addressed through commentary posted online 23
24 Open Microphone Q&A Session 24
25
General Chapter <800> Open Microphone Web Meeting
General Chapter Open Microphone Web Meeting NOTICE TO PARTICIPANTS: To minimize background noise, all lines will be muted upon joining the session. During the meeting, you may ask questions or make
More informationBill Mixon, RPh, MS Senior Associate Gates Healthcare Associates
Bill Mixon, RPh, MS Senior Associate Gates Healthcare Associates 14 pharmacists and 1 epidemiologist make up the committee USP staff FDA and CDC representatives have input but do not vote Call for Candidates
More informationENVIRONMENTAL MONITORING
ENVIRONMENTAL MONITORING Assessment and verification of the adequacy of the aseptic compounding environment is essential. Environmental monitoring programs are designed to promptly identify potential sources
More informationUSP Chapter <797> Update on Recent Revisions
USP Chapter Update on Recent Revisions Claudia C. Okeke, Ph.D., R.Ph. Scientific Fellow United States Pharmacopeia NABP Annual Meeting Tuesday, May 20, 2008 Members of the SCC Committee Chair - David
More informationUnderstanding USP 797
DDK Scientific, Corp. Raul Duarte June 2008 Copyright DDK Scientific, Corp. 2008, 2009 DDK Scientific, Corp. Proprietary The purpose of USP 797 is to prevent harm and fatality to patients that could result
More informationRules for Compounded Sterile Preparations (CSPs)
Introduction: Despite the attention in this document to describe the provision, maintenance, and evaluation of air quality, the avoidance of direct or physical contact contamination is paramount. Since
More informationNew Mexico Register / Volume XXVI, Number 5 / March 16, 2015
This is an amendment to 16.19.36 NMAC, Sections 2, 6, 7, 11, 13 and 15, effective 03-22-2015. 16.19.36.2 SCOPE: All facilities as defined in Paragraph (1), (2), (5) [and (7)] through (11) and (15) of Subsection
More informationFDA and the Compounding Pharmacy
FDA and the Compounding Pharmacy Scott Sutton, Ph.D. scott.sutton@microbiol.org 41 Overview of Presentation The Recent Events GCP and GMP Basics the 483 Review H.R. 3204 Outsourcing Facility Preparation
More informationAMENDED January 27, 2015
Proposed Language To Amend 1735 in Article 4.5 of Division 17 of Title 16 of the California Code of Regulations to read as follows: 1735. Compounding in Licensed Pharmacies. (a) Compounding means any of
More informationQualification of an Environmental Monitoring Program
[ Scott Sutton Qualification of an Environmental Monitoring Program Scott Sutton Microbiology Topics discusses various topics in microbiology of practical use in validation and compliance. We intend this
More informationBRIEFING 797 Pharmaceutical Compounding Sterile Preparations,
BRIEFING 797 Pharmaceutical Compounding Sterile Preparations, USP 39 page 626. It is proposed to revise this chapter to improve clarity, respond to stakeholder input, and reflect new science. Major edits
More informationThe Microbial Bioburden of USP 797 Compliance. Simplifying Environmental Quality and Control Practices for Pharmaceutical Compounding
The Microbial Bioburden of USP 797 Compliance Simplifying Environmental Quality and Control Practices for Pharmaceutical Compounding PathCon Laboratories Fall 2009 Table of Contents Introduction a primer
More informationUSP <797> Cleanroom Design and Environmental Monitoring. Andrew King, USP <797> Specialist CETA Member RCCP-SC
USP Cleanroom Design and Environmental Monitoring Andrew King, USP Specialist CETA Member RCCP-SC Objectives The objectives of this presentation: To summarize basic cleanroom concepts and how
More informationGuidance for Industry
Guidance for Industry Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products For questions on the content of the guidance,
More informationRE: Comments on USP 800 Hazardous Drugs Handling in Healthcare Settings
July 30, 2014 U.S. Pharmacopeial Convention RE: Comments on USP 800 Hazardous Drugs Handling in Healthcare Settings Submission via electronic means to CompoundingSL@usp.org The American Industrial Hygiene
More informationASHP Guidelines on Compounding Sterile Preparations
Drug Distribution and Control: Preparation and Handling Guidelines 75 ASHP Guidelines on Compounding Sterile Preparations Purpose The compounding of medications is a fundamental part of pharmacy practice.
More informationcgmp Challenges for Cord Blood Banks
cgmp Challenges for Cord Blood Banks Donna M. Regan, MT(ASCP)SBB St. Louis Cord Blood Bank @ SSM Cardinal Glennon Children s s Medical Center Cord Blood Bank processing facility challenges What does cgmp
More informationDRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Guidance for Industry Current Good Manufacturing Practice Interim Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act DRAFT GUIDANCE This guidance document is
More informationMicrobiology and Auditing. Don Singer
Microbiology and Auditing Don Singer ASQ Northeast Pharmaceutical GMP/Quality Conference 2011 Through the eyes of a Microbiologist Microbiology Audit = Inspection / Investigation Systematic Auditing Planning
More informationRaleigh, NC May 12 th & 13 th 2016. Meeting The New ISO Cleanroom Standards And Changing EU Guidance How Will You Comply?
Raleigh, NC May 12 th & 13 th 2016 Meeting The New ISO Cleanroom Standards And Changing EU Guidance How Will You Comply? The International Cleanroom Standards (ISO 14644-1 & 2) have been updated, these
More informationJohn Keel, CPA State Auditor. An Audit Report on Inspections of Compounding Pharmacies at the Board of Pharmacy. August 2015 Report No.
John Keel, CPA State Auditor An Audit Report on Inspections of Compounding Pharmacies at the Board of Pharmacy Report No. 15-039 An Audit Report on Inspections of Compounding Pharmacies at the Board of
More information4729-16-11 Hazardous Drugs Compounded by a Prescriber.
ACTION: Original DATE: 11/30/2015 8:57 AM 4729-16-11 Hazardous Drugs Compounded by a Prescriber. (A) A facility where a prescriber is compounding or handling hazardous drugs shall be licensed as a terminal
More information48 th Annual Meeting. On the Radar: Regulatory Basics. Regulatory Agencies. The Joint Commission. Disclosure. Objectives. The Joint Commission
48 th Annual Meeting On the Radar: Regulatory Basics Alissa Voils, PharmD, MSHA Assistant Director, Inpatient Operations UF Health Shands Hospital Regulatory Agencies The Joint Commission (TJC) Florida
More informationAccreditation of a Dispensing and Pharmacy Assistant programme, Boots UK
Accreditation of a Dispensing and Pharmacy Assistant programme, Boots UK Report of an accreditation event, 19 November 2010 Introduction The General Pharmaceutical Council (GPhC) is the statutory regulator
More informationEnvironmental Monitoring of Clean Rooms
Environmental Monitoring of Raul Duarte President DDK Scientific, Corp. Copyright DDK Scientific, Corp. 2008, 2009, DDK Scientific, Corp. Proprietary A manufacturing facility for pharmaceutical products
More informationThe use of risk assessment tools for microbiological assessment of cleanroom environments. by Tim Sandle
The use of risk assessment tools for microbiological assessment of cleanroom environments by Tim Sandle Email: tim.sandle@bpl.co.uk / timsandle@btinternet.com Web: www.pharmig.blogspot.com Environmental
More informationENVIRONMENTAL TESTING & MONITORING: Deciphering Compliance Requirements for Pharmaceutical and Medical Device Manufacturers A WHITE PAPER
A WHITE PAPER ENVIRONMENTAL TESTING & MONITORING: Deciphering Compliance Requirements for Pharmaceutical and Medical Device Manufacturers By Scott Mackin A WHITE PAPER ENVIRONMENTAL TESTING & MONITORING:
More informationManufacturing. Environmental Monitoring Particle Counts Are Easy B IOP ROCESSTECHNICAL. Scott E. Mackler
B IOP ROCESSTECHNICAL Environmental Monitoring Particle Counts Are Easy Scott E. Mackler Manufacturing pharmaceutical and biotechnology products requires that the appropriate level of quality be designed
More information7 Deadly Myths of USP 797 Webinar Q&A By Eric Kastango
7 Deadly Myths of USP 797 Webinar Q&A By Eric Kastango Q: Should gowns that tie in back be used in a clean room? A: The chapter states: a non-shedding gown with sleeves that fit snugly around the wrists
More informationPatient Safety and Peak Performance Through Pharmacy Training
Pharmacy Training Article Authors: Peter Campanella PharmD, Director of Professional Services Marian Robinson, VP Marketing Baxa Corporation Patient Safety and Peak Performance Through Pharmacy Training
More informationA Stability Program for the Distribution of Drug Products
A Stability Program for the Distribution of Drug Products Teresa I. Lucas*, Rafik H. Bishara, and Robert H. Seevers Drug products must be transported in a manner that ensures products will be maintained
More information800 HAZARDOUS DRUGS HANDLING IN HEALTHCARE SETTINGS
BRIEFING 800 Hazardous Drugs Handling in Healthcare Settings. Because there is no existing USP chapter for this topic, the Compounding Expert Committee and the Compounding with Hazardous Drugs Expert Panel
More informationEverything you want to know about USP 797
Everything you want to know about USP 797 Dr. Linda D. Lee Director of Operations Waste Management Healthcare Solutions September. 22, 2009 Goals High level understanding of USP 797 Who does it apply too
More informationPl a n o TX 75075-7525 Producer of Ste rile Dr u
- 12/ 1 9 / 2 0 14* 2 7 43 W 1 5 t h St Pl a n o TX 75075-7525 Producer of Ste rile Dr u This document lists observations made by the FDA rcpresentativc(s) during the inspection of your facility. They
More informationAnnex 9 Guide to good storage practices for pharmaceuticals 1
World Health Organization WHO Technical Report Series, No. 908, 2003 Annex 9 Guide to good storage practices for pharmaceuticals 1 1. Introduction 125 2. Glossary 126 3. Personnel 128 4. Premises and facilities
More informationQuality Systems Appropriate for Extemporaneously Prepared Early Phase Clinical Trial Materials. Agenda Topics for Discussion
Quality Systems Appropriate for Extemporaneously Prepared Early Phase Clinical Trial Materials Richard Hoffman, MS Eli Lilly & Co. Principal Consultant - Regulatory PDA/FDA Joint September 20 th, 2011
More information2014, That Was The Year That Was Greg Baran, RPh, MA, FMPA Baran Consulting LLC
2014, That Was The Year That Was Greg Baran, RPh, MA, FMPA Baran Consulting LLC Objectives 1. Review the changes to the pharmacy practice act related to sterile compounding. 2. Understand the role of the
More information2016 > Emcure Pharmaceuticals Limited 3/3/16
Seite 1 von 7 U.S. Food and Drug Administration Protecting and Promoting Your Health Emcure Pharmaceuticals Limited 3/3/16 Department of Health and Human Services Public Health Service Food and Drug Administration
More informationpatient safety A commitment to GE Healthcare
GE Healthcare A commitment to patient safety GE Healthcare is committed to providing radiopharmaceuticals that are compounded and dispensed accurately. Quality assurance and patient safety are the cornerstones
More informationBEHAVIOUR EXPERIENCE MEDIA FILL QUALIFICATION TRAINING MONITORING GOWNING PERSONAL ATTRIBUTES QUALIFICATION
QUALIFICATION OF ASEPTIC OPERATORS Jaap Koster EXPERIENCE BEHAVIOUR MEDIA FILL QUALIFICATION TRAINING MONITORING GOWNING QUALIFICATION PERSONAL ATTRIBUTES 2 TRAINING GENERAL PRINCIPLES Personnel should
More informationRisk-Based Environmental Monitoring. Marsha Stabler Hardiman Senior Consultant Concordia ValSource Wednesday September 17, 2014 FDA/PQRI
Risk-Based Environmental Monitoring Marsha Stabler Hardiman Senior Consultant Concordia ValSource Wednesday September 17, 2014 FDA/PQRI Presenter Marsha Stabler Hardiman Over 20 years experience in the
More informationHazardous Drug. Cleanroom. Standards
Hazardous Drug Cleanroom Standards Module 3 Table of Contents Section A... 1 A.1 International Standards Organization (ISO) Classifications... 1 A.2 Hazardous Drug Cleanroom and Anteroom... 1 A.2.1 Location
More informationUSP <797> A Road to Compliance The New Mexico Board of Pharmacy
USP A Road to Compliance The New Mexico Board of Pharmacy What is the USP? The United States Pharmacopeia and The National Formulary (USP-NF) is a compilation of drug monographs, biologics, medical
More informationSTERILE COMPOUNDING MEDICATION ERRORS OF CONTAMINATION: WHEN TRAGEDY DRIVES CHANGE JULIE STRICKLAND, PHARMD
STERILE COMPOUNDING MEDICATION ERRORS OF CONTAMINATION: WHEN TRAGEDY DRIVES CHANGE JULIE STRICKLAND, PHARMD STERILE COMPOUNDING MEDICATION ERRORS OF CONTAMINATION: ACTIVITY DESCRIPTION Particularly in
More informationGuidelines for Outsourcing Pharmaceutical Compounding Services: A Tool for Healthcare Organizations
Guidelines for Outsourcing Pharmaceutical Compounding Services: A Tool for Healthcare Organizations June 30, 2014 Guidelines for Outsourcing Pharmaceutical Compounding Services: A Tool for Healthcare Organizations
More informationCommentary USP 36-NF 31. Excerpt Related to General Chapter <17> Prescription Container Labeling
Commentary USP 36-NF 31 Excerpt Related to General Chapter Prescription Container Labeling In accordance with USP s Rules and Procedures of the Council of Experts ( Rules ), USP publishes all proposed
More informationBasic Requirements For Aseptic Manufacturing Of Sterile Medicinal Products A Comparison Between Europe And USA
Basic Requirements For Aseptic Manufacturing Of Sterile Medicinal Products A Comparison Between Europe And USA Wissenschaftliche Prüfungsarbeit zur Erlangung des Titels Master of Drug Regulatory Affairs
More informationCord Blood Licensure. Session 2C: Advanced Cell Therapies April 11, 2013
Cord Blood Licensure Session 2C: Advanced Cell Therapies April 11, 2013 Objectives Describe rationale for cord blood licensure Cite licensure regulations Illustrate a case study of one program s pathway
More informationCHAPTER 17 STERILE PRODUCT COMPOUNDING 17-1
CHAPTER 17 STERILE PRODUCT COMPOUNDING 17-1 Sterile Product Compounding Reference: 1) United States Pharmacopeia chapter 797 (USP) 2) CMS: 482.25(b)(1) - All compounding, packaging, and dispensing
More informationI. Objectives. Justification for clinical education
NC STATE UNIVERSITY RESIDENCY PROGRAM IN VETERINARY CLINICAL PHARMACY The College of Veterinary Medicine, North Carolina State University, is offering a residency program in Veterinary Clinical Pharmacy
More informationDesign, Operation and Management of GTP/GMP Cell Engineering Facilities
Design, Operation and Management of GTP/GMP Cell Engineering Facilities Scott R. Burger, MD Advanced Cell & Gene Therapy BFDA 2007 International Symposium on Regulation of Human Cell and Tissue- Based
More informationHospital Pharmacy Automation: Drug Storage and Retrieval
WHITE PAPER USP CHAPTER 797 CLEAN ROOM APPLICATION Hospital Pharmacy Automation: Drug Storage and Retrieval The technical information regarding USP Chapter (797) and the performance of the Swisslog device
More informationGUIDELINES FOR NUCLEAR PHARMACY TECHNICIAN TRAINING PROGRAMS
GUIDELINES FOR NUCLEAR PHARMACY TECHNICIAN TRAINING PROGRAMS Prepared by Ad Hoc Committee on Nuclear Pharmacy Technicians Nuclear Pharmacy Section Academy of Pharmacy Practice and Management American Pharmaceutical
More informationVersion 1.0 November 2013 Developed by: Working group of the HPAI Aseptic Services Special Interest Group (ASSIG)
(H-PIC\S) Version 1.0 November 2013 Developed by: Working group of the HPAI Aseptic Services Special Interest Group (ASSIG) The working group of the HPAI ASSIG was chaired by: Aisling Collins BSc (Pharm),
More informationExtemporaneously Prepared Early Phase Clinical Trial Materials
Extemporaneously Prepared Early Phase Clinical Trial Materials Richard Hoffman, MS, RAC Eli Lilly & Co. Regulatory Advisor International Consortium for Innovation & Quality in Pharmaceutical Development
More informationPrinciples. of Pharmaceutical Facility Design. Full Time Part Time Online. www.dpseng.com.sg
Principles of Pharmaceutical Facility Design Full Time Part Time Online www.dpseng.com.sg Contents 1. Welcome 2. Programme Overview 3. Programme Content www.dpseng.com.sg 2 Welcome Transition into a new
More informationEnvironmental Monitoring
Environmental Monitoring Purpose of Environmental Monitoring Critical process within the pharmaceutical and biotechnology industries. Determines the microbial and particulate content of cleanroom air and
More informationGuidance for Industry: Starting Material Supplier Management
Guidance for Industry: Starting Material Supplier Management Version 1.0 Drug Office Department of Health. Contents 1. Introduction... 3 2. Purpose of this document... 3 3. Scope... 3 4. Selecting and
More informationOn-Site GMP Training GMP COMPLIANCE TECHNICAL
PharmaNet On-Site GMP Training GMP COMPLIANCE TECHNICAL 284 E Lake Mead Pkwy Suite C-278 Henderson, NV 89015 Phone: 702-558-0094 Fax: 702-558-0079 www.gmpseminars.com Key to Level of Program Level A: Program
More informationVeterinary Compounding
Veterinary Compounding Veterinarians occasionally use compounded preparations to meet a specific patient s medical need. The purpose of this brochure, created jointly by the Animal Health Institute (AHI),
More informationUSP <797> Introduction
Pharmaceutical Compounding Sterile Preparations Summary (Added by MS) This document summarizes the current version of USP , specifically as it pertains to environmental conditions, worker and
More informationMonitoring. Compliant and Reasonable. 5-6 May 2015, Berlin, Germany
Environmental Monitoring Workshops How to Establish an Environmental Monitoring Programme Interpretation of OOS Results Compliant and Reasonable 5-6 May 2015, Berlin, Germany SPEAKERS: Oxoid, UK Sauflon
More informationDraft guidance for registered pharmacies preparing unlicensed medicines
Draft guidance for registered pharmacies preparing unlicensed medicines January 2014 1 The General Pharmaceutical Council is the regulator for pharmacists, pharmacy technicians and registered pharmacies
More informationThe proposed chapter is posted online at www.usp.org/usp-nf/notices/general-chapterhazardous-drugs-handling-healthcare-settings
BRIEFING 800 Hazardous Drugs Handling in Healthcare Settings, PF 40(3) [May Jun. 2013]. Based on the public comments received for the proposed 800 in PF 40(3), the USP Compounding Expert Committee has
More informationThe United States Pharmacopeia
INTERNATIONAL MEETING OF WORLD PHARMACOPOEIAS 29 February to 2 March 2012 The United States Pharmacopeia Angela G. Long, M.S. Senior Vice President, Global Alliances and Organizational Affairs Roger L.
More informationGuidance for Industry
Guidance for Industry Process Validation: General Principles and Practices U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center
More informationVia email Allison.Benz@tsbp.state.tx.us
1/23/15 Ms. Allison Benz, R.Ph., M.S. Director of Professional Services Texas State Board of Pharmacy William P. Hobby Building 333 Guadalupe Street, Suite 3-600 Austin, Texas 78701 Via facsimile transmission:
More informationGMP ANNEX 1 REVISION 2008, INTERPRETATION OF MOST IMPORTANT CHANGES FOR THE MANUFACTURE OF STERILE MEDICINAL PRODUCTS
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 032-2 8 January 2010 RECOMMENDATION GMP ANNEX 1 REVISION 2008, INTERPRETATION OF MOST IMPORTANT CHANGES FOR THE MANUFACTURE
More informationUSP NF General Chapter <797> Pharmaceutical Compounding Sterile Preparations Copyright 2011 The United States Pharmacopeial Convention
2 0 12 USP 35 NF 30 USP NF General Chapter Pharmaceutical Compounding Sterile Preparations Copyright 2011 The United States Pharmacopeial Convention USP 35 Physical Tests / 797 Pharmaceutical Compounding
More informationCLEAN ROOM MONITORING REGULATORY STANDARDS
CLEAN ROOM MONITORING REGULATORY STANDARDS Air Classification as per Schedule M Maximum permitted number of particles / m3 equal or above at rest in operation 0.5µm 5.0µm 0.5µm 5.0µm A 3,520 29 3,500 29
More informationCatalog. Global Education. and Training. Global Expertise Trusted Standards Improved Health
Global Education Catalog 2013 2014 and Training Global Expertise Trusted Standards Improved Health USP s mission is to improve global health through public standards and related programs that help ensure
More informationEU GMP Annex 1 Update 2008: Airborne Particle Counting
EU GMP Annex 1 Update 2008: Airborne Particle Counting Airborne Particle Counting for Pharmaceutical Facilities: Update 2008, EU GMP Annex 1 Morgan Polen - VP of Applications Technology, Lighthouse Worldwide
More informationLibrary Guide: Pharmaceutical GMPs
Library Guide: Pharmaceutical GMPs Table of Contents Overview...3 Courses Listed by Functional Area... 4 Course Descriptions: A Step-by-Step Approach to Process Validation (PHDV79)... 7 A Tour of the FDA
More informationQuality Assurance. Disclosure for Lilli Møller Andersen. No relevant financial relationships exist for any issue mentioned in this presentation
Quality Assurance Disclosure for Lilli Møller Andersen No relevant financial relationships exist for any issue mentioned in this presentation Agenda Quality Assurance Quality Management System Quality
More informationTABLE OF CONTENTS COMMITTEE MEMBERS... 4 ABBREVIATION LIST... 7 DEFINITIONS... 8 INTRODUCTION... 10 GENERAL PROVISIONS... 11
Prepared by Nuclear Pharmacy Compounding Practice Committee Section on Nuclear Pharmacy Practice Academy of Pharmacy Practice and Management (APPM) American Pharmaceutical Association (APhA) Nuclear Pharmacy
More informationPharmaceutical Wholesaler Site Inspection Checklist
Pharmaceutical Wholesaler Site Inspection Checklist Date and time of inspection: Legal business name and plant name: Location (address): Phone number: Fax number: Email address: Web site URL: Contact Person:
More informationParticle Monitoring Requirements in Pharmaceutical Cleanrooms
Particle Monitoring Requirements in Pharmaceutical Cleanrooms All drugs must be manufactured in accordance with the current Good Manufacturing Practice (cgmp) regulations. Pharmaceutical manufacturers
More informationSelf-Assessment Test Pharmacy Technician Roles in Sterile IV Compounding: Challenges, Opportunities, and Competencies
There are 20 questions associated with this self-assessment test. 1. A regular activity performed in exchange for payment or a position in which one is employed is the definition of a: a. Career. b. Job.
More informationUnited States Pharmacopeia (USP) Quality Standards for Dietary Supplements. Nandu Sarma, PhD, RPh. Director, Dietary Supplements
United States Pharmacopeia (USP) Quality Standards for Dietary Supplements Nandu Sarma, PhD, RPh. Director, Dietary Supplements ACPM webinar, July 17, 2014 Objectives Describe the dietary supplement regulations
More informationCase Study Neubau einer Parenteralia Fabrik 3. GMP-Forum, Kirchzarten 28. September 2012, Basel. Philip Schneider, F.
3. GMP-Forum, Kirchzarten 28. September 2012, Basel Philip Schneider, F. Hoffmann-La Roche Content Introduction Decontamination cycle Set-up and change over Aseptic connections Glove handling and testing
More informationDISCUSSION TOOL PRESENTED TO THE AABB CT REGULATORY AFFAIRS SUBSECTION
1 US FDA Form 483: A Case Study DISCUSSION TOOL PRESENTED TO THE AABB CT REGULATORY AFFAIRS SUBSECTION DEVELOPED BY FRAN RABE 2 Introduction This case study is intended to extract portions of information
More informationBy Lawrence A. Trissel, B.S., R.Ph., FASHP. Modified from the original presentation March 9, 2006
USP Chapter : Beyond Use Dating, Stability, and Storage Modified from the original presentation March 9, 2006 By Lawrence A. Trissel, B.S., R.Ph., FASHP Supported by an unrestricted educational grant
More informationProfessional Standards and Guidance for the Sale and Supply of Medicines
Professional Standards and Guidance for the Sale and Supply of Medicines About this document The Code of Ethics sets out seven principles of ethical practice that you must follow as a pharmacist or pharmacy
More informationCONCEPTS OF FOOD SAFETY QUALITY MANAGEMENT SYSTEMS. Mrs. Malini Rajendran
CONCEPTS OF FOOD SAFETY AND QUALITY MANAGEMENT SYSTEMS Mrs. Malini Rajendran Brief background 1963 - The Codex Alimentarius Commission was created by FAO and WHO to develop food standards, guidelines and
More informationCareer-Technical Credit Transfer (CT)² Pharmacy Technician Career Technical Assurance Guide (CTAG) August 26, 2012
Career-Technical Credit Transfer (CT)² Pharmacy Technician Career Technical Assurance Guide (CTAG) August 26, 2012 The following programs/courses, indicated by a Career-Technical Articulation Number (CTAN),
More informationGeneral Guide to USP Proposed Chapter <800>: Hazardous Drugs Handling in Healthcare Settings
General Guide to USP Proposed Chapter : Hazardous Drugs Handling in Healthcare Settings DISCLAIMER: This general guide is not designed to be an all-inclusive review of USP . PCCA provides this
More informationCleanroom. For. Sterile Manufacturing Facilities
Cleanroom For Sterile Manufacturing Facilities Praphon Angtrakool Food and Drug Administration 1 WHO TRS No. 823 Annex 1, 1992 (1) General 17.1 The production of sterile preparations should be carried
More informationChapter. History and Traditional Technician Roles
Chapter 1 History and Traditional Technician Roles 1 9781449629823_CH01_001_014.indd 1 2 History and Traditional Technician Roles Case Study for Discussion Would it be helpful if pharmacists and pharmacy
More informationThe following Good Compounding Practices (GCPs) are meant to apply only to the compounding of drugs by State-licensed pharmacies.
1 NABP Model State Pharmacy Act & Model Rules Appendix B Good Compounding Practices Applicable to State Licensed Pharmacies The following Good Compounding Practices (GCPs) are meant to apply only to the
More informationStep-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry
Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry BY GHULAM A. SHABIR Introduction Methods Validation: Establishing documented evidence that provides a high
More informationIndiana Pharmacy Inspection Report Questions
Pharmacy General Information 1.1 Type of Inspection 1.5 County 1.6 Telephone number 1.7 District 1.8 Is permit properly displayed? 1.9 Controlled Substance Registration (CSR) number 1.10 Controlled Substance
More informationASHP Guidelines on Outsourcing. Sterile Compounding Services
434 Pharmacy Management Guidelines ASHP Guidelines on Outsourcing Sterile Compounding Services Purpose The purpose of these guidelines is to provide an overview of factors and processes for healthcare
More informationH4235 An Act relative to pharmacy practice in the Commonwealth
H4235 An Act relative to pharmacy practice in the Commonwealth Summary THE BOARD OF REGISTRATION IN PHARMACY SECTIONS 2 & 3. The Board of Registration in Pharmacy is expanded to include 13 individuals,
More informationAPPLICATION FOR SITE INSPECTION Eye Bank Association of America
APPLICATION FOR SITE INSPECTION Eye Bank Association of America Complete this application to begin the process for inspection and accreditation by the Eye Bank Association of America (EBAA). See the EBAA
More informationGood Manufacturing Practices (GMP) for Pharmaceutical Excipients
Not for publication. This draft text is for circulation for approval by the Joint Committee and has not been published or otherwise officially promulgated. All rights reserved. This document may be reproduced
More informationRecent Updates on European Requirements and what QPs are expected to do
Recent Updates on European Requirements and what QPs are expected to do QP Forum 28/29 November 2013, Lisbon Dr. Bernd Renger Modified: Georg Goestl 1 Written Conformation for API-Import Actual Status
More informationWorking Party on Control of Medicines and Inspections. Final Version of Annex 15 to the EU Guide to Good Manufacturing Practice
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, regulatory environment, industries under vertical legislation Pharmaceuticals and cosmetics Brussels, July 2001 Working Party on Control
More informationAnnex 2 Stability testing of active pharmaceutical ingredients and finished pharmaceutical products
World Health Organization WHO Technical Report Series, No. 953, 2009 Annex 2 Stability testing of active pharmaceutical ingredients and finished pharmaceutical products 1. Introduction 1.1 Objectives of
More informationInternational Standard ISO 14644
International Standard ISO 14644 Cleanrooms and associated controlled environments Praphon Angtrakool Food and Drug Administration 1 International Standard : ISO 14644 ISO 14644 consists of the following
More information